Drugs / KSR-001-03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05017870 | Dec 2018 → Jun 2019 | dry eye syndrome | Kukje Pharma | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05017844 | Feb 2020 → Feb 2021 | dry eye syndrome | Kukje Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSR-001-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05017844 ↗ |
| Route | Topical | “KSR-001-03 eyedrops recieved one drop to both eyes” NCT05017844 ↗ |